Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bregt S Kappelhoff

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Drugs in R&D|March 22, 2005
Should non-nucleoside reverse transcriptase inhibitors be combined?Bregt S Kappelhoff, Alwin D R Huitema, Jos H Beijnen
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|July 16, 2003
Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatographyBregt S Kappelhoff, Hilde Rosing, Alwin D R Huitema, et al.
Journal of Medical Economics|May 9, 2012
Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the NetherlandsMaarten J Postma, Bregt S Kappelhoff, Marinus van Hulst, et al.
Journal of Medical Economics|March 27, 2013
Author response : economic evaluation of dabigatran etexilateMaarten J Postma, Bregt S Kappelhoff, Marinus van Hulst, et al.
Antiviral Therapy|March 9, 2005
Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN studyBregt S Kappelhoff, Frank van Leth, Thomas R MacGregor, et al.
Anti-Cancer Drugs|June 3, 2005
No pharmacokinetic drug-drug interaction between nevirapine and paclitaxelBregt S Kappelhoff, Alwin D R Huitema, Albert T A Mairuhu, et al.
Clinical Pharmacokinetics|July 21, 2005
Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individualsBregt S Kappelhoff, Alwin D R Huitema, Zeynep Yalvaç, et al.
Clinical Pharmacokinetics|October 29, 2004
Practical guidelines to interpret plasma concentrations of antiretroviral drugsBregt S Kappelhoff, Kristel M L Crommentuyn, Monique M R de Maat, et al.
HIV Clinical Trials|November 25, 2005
Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN studyBregt S Kappelhoff, Alwin D R Huitema, Frank van Leth, et al.
Cost Effectiveness and Resource Allocation : C/E|November 24, 2007
Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the NetherlandsGijs A A Hubben, Jasper M Bos, Christa A Veltman-Starkenburg, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Drugs in R&D|March 22, 2005
Should non-nucleoside reverse transcriptase inhibitors be combined?Bregt S Kappelhoff, Alwin D R Huitema, Jos H Beijnen
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|July 16, 2003
Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatographyBregt S Kappelhoff, Hilde Rosing, Alwin D R Huitema, et al.
Journal of Medical Economics|May 9, 2012
Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the NetherlandsMaarten J Postma, Bregt S Kappelhoff, Marinus van Hulst, et al.
Journal of Medical Economics|March 27, 2013
Author response : economic evaluation of dabigatran etexilateMaarten J Postma, Bregt S Kappelhoff, Marinus van Hulst, et al.
Antiviral Therapy|March 9, 2005
Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN studyBregt S Kappelhoff, Frank van Leth, Thomas R MacGregor, et al.
Anti-Cancer Drugs|June 3, 2005
No pharmacokinetic drug-drug interaction between nevirapine and paclitaxelBregt S Kappelhoff, Alwin D R Huitema, Albert T A Mairuhu, et al.
Clinical Pharmacokinetics|July 21, 2005
Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individualsBregt S Kappelhoff, Alwin D R Huitema, Zeynep Yalvaç, et al.
Clinical Pharmacokinetics|October 29, 2004
Practical guidelines to interpret plasma concentrations of antiretroviral drugsBregt S Kappelhoff, Kristel M L Crommentuyn, Monique M R de Maat, et al.
HIV Clinical Trials|November 25, 2005
Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN studyBregt S Kappelhoff, Alwin D R Huitema, Frank van Leth, et al.
Cost Effectiveness and Resource Allocation : C/E|November 24, 2007
Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the NetherlandsGijs A A Hubben, Jasper M Bos, Christa A Veltman-Starkenburg, et al.
Pageof 2